Remarkably, all the mice of the combination-treated cohort (9 of 9) displayed dramatic tumor regression and long-term survival (Fig. 7e, g, h), indicating that the combination of USP2 inhibition and PD-1/PD-L1 blockade is an especially effective mode of tumor therapy. Here, USP2 is linked to neoplasm.